With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.25637-16-5,4-Bromotetrahydropyran,as a common compound, the synthetic route is as follows.
5- (4-Fluorophenyl) -4-oxo-1,4-dihydropyridazine-3-carboxylic acid ethyl ester (500.0 mg, 1.9 mmol, 1.0 eq) was dissolved in DMF (5 mL) and added Cesium carbonate (1.85 g, 5.70 mmol, 3.0 eq) and 4-bromotetrahydro-2H-pyran (628.7 mg, 3.81 mmol, 2.0 eq) were stirred at 120 C for 5 hours. The reaction was monitored by TLC, and the reaction was concentrated under reduced pressure. Ethyl acetate (15 mL) and water (20 mL) were added, and the layers were separated. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate). Esters = 8: 1 to 2: 1) to obtain the product (342.0 mg, yield: 51.9%).
25637-16-5, The synthetic route of 25637-16-5 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; Nanjing Yaojie Good Health Biological Technology Co., Ltd.; Wu Yongqian; Li Lin; Wan Zhonghui; (107 pag.)CN110041316; (2019); A;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics